Ketolides
WikiDoc Resources for Ketolides |
Articles |
---|
Most recent articles on Ketolides |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Ketolides at Clinical Trials.gov Clinical Trials on Ketolides at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Ketolides
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Ketolides Discussion groups on Ketolides Directions to Hospitals Treating Ketolides Risk calculators and risk factors for Ketolides
|
Healthcare Provider Resources |
Causes & Risk Factors for Ketolides |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Ketolides are antibiotics belonging to the macrolide group. Ketolides are derived from erythromycin by substituting the cladinose sugar with a keto-group and attaching a cyclic carbamate group in the lactone ring. These modifications give ketolides much broader spectrum than other macrolides. Moreover, ketolides are effective against macrolide-resistant bacteria, due to their ability to bind at two sites at the bacterial ribosome. Keytolides block protein synthesis by binding to ribosomal subunits and may also inhibit the formation of newly forming ribosomes.
The only ketolide on the market at this moment is telithromycin, which is sold under the brand name of Ketek.
Another promising ketolide is cethromycin.